Advances in the treatment of secondary and tertiary hyperparathyroidism.

Authors :: Zhang LX
Zhang B
Liu XY
Wang ZM
Qi P
Zhang TY
Zhang Q
Source :: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Dec 06; Vol. 13, pp. 1059828. Date of Electronic Publication: 2022 Dec 06 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Secondary hyperparathyroidism (SHPT) and tertiary hyperparathyroidism (THPT) are common and complicated clinical endocrine diseases. The parathyroid glands maintain endocrine homeostasis by secreting parathyroid hormone to regulate blood calcium levels. However, structural alterations to multiple organs and systems occur throughout the body due to hyperactivity disorder in SHPT and THPT. This not only decreases the patients' quality of life, but also affects mortality. Since current treatments for these diseases remains unclear, we aimed to develop a comprehensive review of advances in the treatment of SHPT and THPT according to the latest relevant researches.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Zhang, Zhang, Liu, Wang, Qi, Zhang and Zhang.)